iRhythm Technologies stock reports 20.1 percent revenue growth

iRhythm Technologies stock stood at USD 111.75 on Nasdaq on September 23, 2026, while the company reported Q2 2026 revenue of USD 224.17 million, up 20.1 percent from the prior year. The latest market picture combines double digit sales growth with a share price 47.3 percent below its 52-week high of USD 212.00.

Revenue beats Q2 expectations

According to MarketBeat, iRhythm generated USD 224.17 million in the quarter ended June 30, 2026, compared with analyst estimates of USD 219.30 million. That represents a revenue beat of USD 4.87 million, or 2.2 percent, while adjusted EPS of USD 0.58 exceeded the consensus estimate of negative USD 0.04 by USD 0.62.

The operating improvement is visible in the cash flow as well. iRhythm produced USD 51.08 million in operating cash flow in Q2 2026, compared with negative USD 26.17 million in Q1 2026, although the company still reported a GAAP net loss of USD 381,000 for the latest quarter.

Vital Connect clears a hurdle

The next valuation question is strategic rather than purely quarterly. Stock Titan reported on September 22, 2026, that the Hart-Scott-Rodino waiting period for the Vital Connect acquisition expired at 11:59 p.m. ET on September 18, 2026.

The transaction is anticipated to close in early October 2026, subject to customary closing conditions, according to the same regulatory filing. The deal could broaden iRhythm's cardiac monitoring platform, but the financial case now depends on combining acquisition execution with continued revenue growth.

Stock remains below yearly high

IRTC had a market capitalization of USD 3,672,374,094 on September 23, 2026. Its 52-week range was USD 100.85 to USD 212.00, placing the latest price USD 10.90 above the low and USD 100.25 below the high.

iRhythm Technologies describes its Nasdaq-listed IRTC business as a digital health company built around wearable biosensors, cloud analytics and the Zio cardiac monitoring platform. The company generated USD 224.17 million in Q2 revenue, making the 20.1 percent year-over-year growth rate the clearest operating benchmark for the stock.